Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride may help improve certain brain function issues linked to dopamine.

This review discusses the roles of hormonal pathways in regulating male sexual function, particularly highlighting the impact of testosterone, and reports no new research findings.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

In this study, finasteride was found to inhibit the dopaminergic system and reduce open-field behaviors in adolescent male rats by decreasing dopamine levels and related proteins.

This study identified significant changes in the expression of nine proteins in the nucleus accumbens of rats treated with finasteride, suggesting potential novel targets for its neuropsychiatric effects.

This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This review discusses the potential link between early postnatal allopregnanolone levels and vulnerability to drug abuse in adulthood, noting a need for more in-depth studies to confirm this relationship.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This study found that neuroactive steroids like DHEA and pregnenolone influence cocaine-induced appetence in mice through their interaction with the ς₁ receptor, suggesting a role in individual vulnerability to addiction.

This chapter discusses charnolopharmacotherapeutics for various medical conditions and suggests antioxidant-loaded nanoparticles may improve treatment by enhancing central nervous system delivery and inducing charnolophagy.

This study found that altering neonatal neurosteroid levels affected anxiety and aversive learning in adult rats, possibly through changes in hippocampal GABAergic functions.

This study found that inhibiting the enzyme 5α-reductase with finasteride counteracted stress-induced prepulse inhibition deficits in socially isolated rats by altering neuroactive steroid concentrations in the brain.

In this review, researchers explored the complex mechanisms behind chemotherapy-induced side effects like nausea, fatigue, and hair loss, and discussed potential strategies using natural agents to manage these toxicities, improving understanding for targeted adjunct therapies.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

This review discusses treatment options for tics in Gilles de la Tourette syndrome, highlighting existing therapies and potential future advancements, but reports no new clinical findings.

This study found that neonatal administration of finasteride reduced sensitivity to alcohol's motor-stimulating effects and increased preference for novelty and initial alcohol consumption in rats, suggesting a role in alcohol vulnerability.

This review examines testosterone's role in male health and aging but reports no new clinical results; the authors highlight the need for further research on optimal testosterone levels to prevent age-related conditions.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

In this study, socially defeated mice showed increased alcohol consumption, and CRF-R1 antagonism selectively reduced drinking in these mice, suggesting a potential treatment target for stress-related alcohol use disorders.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This book discusses current research on polycystic ovary syndrome, including diagnosis, management, and the impact of lifestyle changes, without reporting new clinical results.

This article outlines the scope, publication standards, and authorship responsibilities of the International Journal of KIU, but reports no new research results.

This study observed that drug-naïve first-episode psychosis patients had higher hair cortisol concentrations than healthy controls, and these concentrations correlated with the severity of psychopathology.

This review concludes that anabolic–androgenic steroid abuse may lead to significant neurotoxicity, affecting brain structure, neurotransmitter systems, and increasing the risk of mood disorders and cognitive deficits.

This study found that, although finasteride reduced dihydrotestosterone levels in males with heavy episodic drinking, it did not significantly alter brain activation or craving but was linked to a stronger desire not to drink.

This study provides a detailed overview of 1,295 clinical trials related to alcohol dependence registered on ClinicalTrials.gov, highlighting that 59.15% of these trials have been completed, primarily as interventional studies, with most located in North America.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.